We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Study Reveals Moleclar Mechanism Driving Aggressive Skin Cancer

By LabMedica International staff writers
Posted on 20 Apr 2026

Cutaneous squamous cell carcinoma (cSCC) is the world’s second most common skin cancer, and while many cases are treatable, a subset becomes highly aggressive and therapy‑resistant. More...

Identifying molecular drivers that tip tumors toward invasion and metastasis remains a clinical priority, and understanding how epidermal identity is maintained may help flag high-risk disease earlier. New findings now identify a protein safeguard that preserves epithelial programming and limits the transition to metastatic behavior.

Hebrew University of Jerusalem researchers identified WWOX as a molecular “protein shield” that preserves epithelial identity in cSCC. The study outlines how this protein functions as a primary defense against progression to aggressive disease. Loss of WWOX was linked to transformation of common skin cancer cells into invasive, poorly differentiated forms.

Mechanistically, WWOX stabilizes the p63 protein, a master regulator that maintains epithelial structure and function. When WWOX is intact, p63 remains stable and skin cells retain their identity. When WWOX is lost, p63 levels drop, triggering epithelial‑to‑mesenchymal transition (EMT) that endows cells with migratory properties, enabling invasion and dissemination to the lungs and other organs.

Using advanced genetic models alongside human tissue samples, the investigators showed that combined loss of WWOX and the tumor suppressor p53 markedly accelerated tumor onset. Tumors arising under double deficiency were earlier, more aggressive, and poorly differentiated compared with settings in which WWOX remained functional. In these models, 100% of subjects with dual WWOX–p53 loss developed tumors, versus a much lower percentage in control groups.

Analyses of human tissue microarrays supported the translational relevance: as cSCC advanced, WWOX and p63 levels declined in tandem. According to the authors, this correlation suggests both proteins could serve as clinical biomarkers to help predict which tumors are likely to become dangerous. The findings were published in Proceedings of the National Academy of Sciences under the title “WWOX maintains epidermal identity and suppresses EMT to prevent aggressive cutaneous squamous cell carcinoma.” The results further suggest that restoring WWOX, stabilizing p63, or promoting epithelial differentiation might inhibit EMT and slow tumor growth.

Related Links
Hebrew University of Jerusalem


New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
Thyroid Test
Anti-Thyroid EIA Test
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Molecular Diagnostics

view channel
Image: The platform analyzes cell-free DNA in blood, searching for minute amounts of tumor-derived fragments among background DNA (Image Credit: Adobe Stock)

Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings

Lymphoma can be difficult to distinguish from infections and benign conditions, while definitive diagnosis often depends on surgical tissue sampling and specialized pathology that may not be readily available.... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.